February 21, 2024 - 10:00 am CET
Bad Homburg, Germany
Press Conference Full Year Results 2023
February 27, 2024
London, UK
Morgan Stanley – European MedTech & Services Conference
Fresenius has successfully completed the divestment of fertility services group Eugin. As announced in November 2023, global fertility group IVI RMA (a KKR portfolio company) and GED Capital acquired Eugin for up to €500 million including earn-outs. The transaction has received all regulatory approvals.
The divestment marks another milestone in the implementation of #FutureFresenius and is in line with the company’s commitment to a simplified structure, sharper focus and accelerated performance. Furthermore, the sale proceeds will benefit Fresenius’ financial flexibility.
The sale only comprises the Eugin Group. Fresenius Helios' well-established legacy business of fertility treatments in selected hospitals and outpatient centers of Quirónsalud and Helios Germany will remain with Fresenius Helios and continue to offer fertility treatments.
This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts.
Fresenius does not undertake any responsibility to update the forward-looking statements in this release.
Off to new shores: Here comes the first episode of our new podcast ‘Talk Time – CEO Insights with Michael Sen’. Fresh back from the J.P. Morgan Health Care Conference and the World Economic Forum in Davos. His sketchbook full of impressions, all shared in our podcast.
(Note: Editorial closing date: 25.01.2024 / Recording date: 25.01.2024)
Tune in. The podcast is now available here:
-
Behind the scenes -
![]()
Behind the scenes -
![]()
Behind the scenes -
![]()
Behind the scenes -
![]()
Behind the scenes
Listen on Spotify:
Talk Time – CEO Insights with Michael Sen | Podcast on Spotify
Videopodcast:
Fresenius has successfully completed the divestment of fertility services group Eugin. As announced in November 2023, global fertility group IVI RMA (a KKR portfolio company) and GED Capital acquired Eugin for up to €500 million including earn-outs. The transaction has received all regulatory approvals.
The divestment marks another milestone in the implementation of #FutureFresenius and is in line with the company’s commitment to a simplified structure, sharper focus and accelerated performance. Furthermore, the sale proceeds will benefit Fresenius’ financial flexibility.
The sale only comprises the Eugin Group. Fresenius Helios' well-established legacy business of fertility treatments in selected hospitals and outpatient centers of Quirónsalud and Helios Germany will remain with Fresenius Helios and continue to offer fertility treatments.
This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.
Fresenius Kabi announced today the immediate availability in the U.S. of Posaconazole Injection, a generic substitute for Noxafil®*, for the treatment or prevention of serious fungal infections. It is the newest addition to the company’s portfolio of more than 30 anti-infective molecules.
For more information, please see the website of Fresenius Kabi.
*Noxafil® is a registered trademark of Merck Sharp & Dohme LLC.
Fresenius Kabi announced today the immediate availability in the U.S. of Posaconazole Injection, a generic substitute for Noxafil®*, for the treatment or prevention of serious fungal infections. It is the newest addition to the company’s portfolio of more than 30 anti-infective molecules.
For more information, please see the website of Fresenius Kabi.
*Noxafil® is a registered trademark of Merck Sharp & Dohme LLC.